Logo_AIHTA
  • Deutsch
  • Contact
    • Imprint
      • Privacy Notice
        • Newsletter
          • Sitemap
            Menu_button
            • News
              • About us
                • Research areas
                  • Research Projects
                    • Publications
                      • Search
                        • Announcements
                          • Events
                            • Newsletter
                              • Press release on our reports
                                • Press photos
                                  Video
                                  Video: What is HTA?    
                                  • Home
                                  • News

                                  News

                                  Leiste32


                                  Welcome to the homepage of AIHTA!

                                  AIHTA is an academic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.

                                  In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.

                                  Subscribe to newsletter

                                  Adobestock-215120779-von-peterschreiber-media-klein2
                                  ©stock.adobe.com

                                  Announcement

                                  Role of Public Contributions to the Development of Health Innovations

                                  New (pharmaceutical) products are getting increasingly more expensive. As a result of this trend accessibility of pharmaceuticals decreases. However, not all innovation can be attributed to private companies. Subsequently, the role of public institutions like universities, university spin-offs, and publicly funded biotech start-ups is largely being disregarded at the price negotiations. Public funding in the form of research grants, tax incentives, utilisation of clinical infrastructure or regulatory measures make a major contribution.

                                  Article 57 of the proposed Pharmaceutical Legislation (PL, Directive) will require market authorization applicants to publicly declare any direct financial support for R&D received from public authorities. The aim of our research (funded by EU Horizon Europe Grant Agreement Number 101095593) is to increase transparency in (pharmaceutical) R&D to mitigate the risk of market failure associated with information asymmetry by analyzing pharmaceutical R&D expenditures of bringing a new medicine to the market and which factors influence these expenditures and to identify the categories needed to capture direct or indirect public contributions to R&D, to provide a framework for standardized reporting of public contributions and to reduce ambiguity in the interpretation of “direct” and “indirect” public contributions.

                                  The report is the first output of the project HI-PRIX (WP2, sub-deliverable 2.2).

                                  Publication: HTA Project Report No. 158: https://eprints.aihta.at/1499/
                                  Contact: Claudia Wild

                                  More...

                                  Newsletter_preview

                                  Newsletter

                                  Note: this content is only available in German.

                                  Inhalt

                                  • Editorial: Klimaschutz - wer schnell agiert, hilft doppelt
                                  • Leitlinien und derzeitiges Disease-Management-Programm für Depression im Vergleich
                                  • Nusinersen, Onasemnogen-Abeparvovec, Risdiplam und Kombinationstherapien bei SMA-Patient*innen
                                  • Progressionshemmende Brillengläser für Kinder und Jugendliche mit fortschreitender Myopie
                                  • HTA-Methoden zur Unterstützung der Gesundheitsgerechtigkeit
                                  • Termine
                                  • Themen-Vorschau
                                  Print Zur Druckversion...
                                  2186
                                  ©stock.adobe.com

                                  Announcement

                                  Horizon Scanning in Oncology - Fact Sheets

                                  We are pleased to introduce you five new Fact Sheets.

                                  Fact Sheet No. 157 (November 2023)
                                  Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM)

                                  Fact Sheet No. 158 (November 2023)
                                  Pembrolizumab (Keytruda®) with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC)

                                  Fact Sheet No. 159 (November 2023)
                                  Adagrasib (Krazati®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) 

                                  Fact Sheet No. 160 (November 2023)
                                  Momelotinib (Omjjara®) for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (PMF), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis

                                  Fact Sheet No. 161 (November 2023)
                                  Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

                                  More...

                                  Adobestock-299175978-von-oatawa1
                                  ©stock.adobe.com

                                  Announcement

                                  Registries in Austria and their utilisation for healthcare improvement

                                  Registries are systems for collecting observational data on patients in a database. They can be used by decision-makers to improve healthcare. However, the number and type of existing registries in Austria are unknown. Therefore, the aim of this report was to provide an overview of the Austrian registry landscape and to present the quality and characteristics of selected registries. Furthermore, it was a goal to examine the utilisation of Austrian registries and whether some areas need further development.

                                  Publication: HTA Project Report No. 157: https://eprints.aihta.at/1489/
                                  Contact: Christoph Strohmaier


                                   

                                  More...

                                  Adobestock-103301573-ohne-schrift2
                                  ©stock.adobe.com

                                  Announcement

                                  Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity

                                  For children, adolescents and adults with overweight or grade 1 obesity, group programmes are offered which include content on nutrition, exercise and behaviour. However, it is a challenge to reach the respective target groups and to retain the participants in the programme for the entire duration. Based on the reviewed literature, numerous strategies for recruiting target groups and improving programme adherence were identified. In addition, an overview of existing programmes in German-speaking countries was provided.

                                  Publication: HTA Project Report No. 155: https://eprints.aihta.at/1486/
                                  Contact: Inanna Reinsperger

                                  More...

                                  Adobestock-133673854-von-doris-oberfrank-list
                                  ©stock.adobe.com

                                  Announcement

                                  SMA therapies: Mid-to-long-term follow-up of patients treated >=24 months with nusinersen or onasemnogene abeparvovec, and >=12 months with risdiplam (mono/combination therapy)

                                  Since 2017, three therapies have been approved by the FDA and EMA for the treatment of SMA patients: The results show clinically relevant improvements in motor skills in SMA type 1 patients, especially in patients with early treatment initiation and >=2 SMN2 copies, as well as stabilisation of health status in SMA type 2 to 4 patients. In all studies reporting these outcomes, no significant improvements in respiratory and nutritional function were recorded regardless of SMA type and therapy used, with most studies reporting no change or an increase in the need for ventilation and nutritional support.

                                  20 observational studies and 1 RCT were included in the synthesis, reporting on a total of 1,374 patients. 15 studies investigated nusinersen in 948 patients, one study was identified on onasmenogene abeparvovec and investigated 12 patients, and two studies investigated risdiplam in 221 patients. 193 patients received combination therapy.

                                  Publication: Policy Brief Nr. 001, 2. Update: https://eprints.aihta.at/1485/
                                  Contact: Claudia Wild

                                  More...

                                  2185
                                  ©stock.adobe.com

                                  Announcement

                                  Horizon Scanning in Oncology - Fact Sheets

                                  We are pleased to introduce you six new Fact Sheets.

                                  Fact Sheet No. 151 (October 2023)
                                  Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL)

                                  Fact Sheet No. 152 (October 2023)
                                  Elranatamab (Elrexfio®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM)

                                  Fact Sheet No. 153 (October 2023)
                                  Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC)

                                  Fact Sheet No. 154 (October 2023)
                                  Dostarlimab (Jemperli®) with carboplatin and paclitaxel for the treatment of mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) primary advanced or recurrent endometrial cancer (EC)

                                  Fact Sheet No. 155 (October 2023)
                                  Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

                                  Fact Sheet No. 156 (October 2023)
                                  Rucaparib (Rubraca®) as monotherapy for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer

                                  More...

                                  Newsletter_preview

                                  Newsletter

                                  Note: this content is only available in German.

                                  Inhalt

                                  • Editorial: Die andere Seite der Medaille: Verdrängungseffekte durch teure Therapien sichtbar machen
                                  • Bupropion, Cytisin, Nicotin und Vareniclin zur Tabakentwöhnung bei schwerer Tabakabhängigkeit
                                  • Wirksamkeit nicht-medikamentöser Verfahren bei Restless-Legs-Syndrom
                                  • Register in Österreich: Verwendung zur Verbesserung der Gesundheitsversorgung
                                  • Adipositas-Gruppenprogramme: Strategien zum Erreichen der Zielgruppen und zur Verbesserung der Programmadhärenz
                                  • Termine
                                  • Themen-Vorschau
                                  Print Zur Druckversion...
                                  Adobestock-456376994-von-crystal-light1
                                  ©stock.adobe.com

                                  Announcement

                                  Image-guided spinal injections in treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques

                                  We performed a guideline synopsis to identify indications for the use of image-guided interventions and summarise the subsequent recommendations. We also considered potential organisational or social aspects.

                                  Ten clinical guidelines fulfilled our eligibility criteria. Seven were related to epidural injections in four indications (axial discogenic pain, disc herniation, spinal stenosis, post-surgery syndrome) and five clinical guidelines on facet joint injections in one indication (axial facet joint pain). The majority are related to the lumbar spine. Only three guidelines on epidural injections and four on facet joint injections provided recommendations on imaging modalities.The synopsis of recommendation for epidural injections is inconsistent in two clinical indications, axial discogenic pain and spinal stenosis, with con-flicting recommendations across CGs. The same is true for facet joint injections, for both nerve block and intraarticular injections. The other two clinical indications for epidural injections, disc herniation and post-surgery syndrome, included both strong and weak recommendations for using epidural injections.

                                  Publication: HTA Project Report No. 156: https://eprints.aihta.at/1477/
                                  Contact: 
                                  Gregor Goetz

                                  More...

                                  2184
                                  ©stock.adobe.com

                                  Announcement

                                  Horizon Scanning in Oncology - Fact Sheets

                                  We are pleased to introduce you five new Fact Sheets.

                                  Fact Sheet No. 146 (September 2023)
                                  Brentuximab vedotin (Adcetris®) in combination with doxorubicin, vinblastine and dacarbazine for previously untreated CD30+ Stage III or IV Hodgkin lymphoma

                                  Fact Sheet No. 147 (September 2023) 
                                  Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation

                                  Fact Sheet No. 148 (September 2023)
                                  Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC)

                                  Fact Sheet No. 149 (September 2023)
                                  Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM)

                                  Fact Sheet No. 150 (September 2023)
                                  Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML)

                                  More...

                                  « < ... 3 4 5 6 7 ... > »
                                  Displaying results 41 to 50.
                                  • News
                                    • Announcements
                                      • Events
                                        • Newsletter
                                          • Press release on our reports
                                            • Press photos
                                            • About us
                                              • Evaluation
                                                • History
                                                  • Methods
                                                    • Team
                                                      • Shareholder & organization chart
                                                        • Stakeholder involvement
                                                          • Press clippings
                                                          • Research areas
                                                            • Oncology
                                                              • High tech medicine
                                                                • Rehabilitation and occupational therapy
                                                                  • Prevention and screening
                                                                    • Psychological & psychiatric interventions
                                                                      • Health economics
                                                                        • European collaboration
                                                                          • HTA-methods & steering instruments
                                                                            • Complementary medicine
                                                                            • Research Projects
                                                                              • Synopsis of current research projects
                                                                                • Synopsis of completed research projects
                                                                                  • Decision Support Documents for the Austrian Appraisal Board
                                                                                    • HTA-Information Service Rapid Reviews
                                                                                      • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                                                                        • Horizon Scanning of Medicines - Reports and Fact Sheets
                                                                                          • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                                                                            • Evaluation of individual medical procedures - Reports
                                                                                              • All projects in an overview
                                                                                              • Publications
                                                                                                • Repository
                                                                                                  • HTA-Newsletter
                                                                                                    • Annual Reports
                                                                                                    • Search
                                                                                                      Netzwerk
                                                                                                      • Eunethta
                                                                                                      • Ebm
                                                                                                      • Inahta
                                                                                                      • Dexhelpp
                                                                                                      Shareholder
                                                                                                      • Bmfg
                                                                                                      • Sv
                                                                                                      • Wgfond
                                                                                                      • Noe
                                                                                                      • Ooghfond
                                                                                                      • Ghls
                                                                                                      • Tirol
                                                                                                      • Vorarlberg
                                                                                                      • Kghfond
                                                                                                      • Ghpf
                                                                                                      • Burgef
                                                                                                      • Contact
                                                                                                        • Imprint
                                                                                                          • Privacy Notice
                                                                                                            • Newsletter
                                                                                                              • Sitemap
                                                                                                                © 2025 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                                • Log in